Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 44,748 shares of Metacrine stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $0.50, for a total transaction of $22,374.00. Following the completion of the sale, the chief executive officer now owns 922,510 shares of the company’s stock, valued at approximately $461,255. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of NASDAQ:MTCR traded down $0.01 during midday trading on Wednesday, hitting $0.52. The stock had a trading volume of 918,847 shares, compared to its average volume of 2,015,731. The company’s 50-day moving average price is $0.52 and its 200-day moving average price is $1.08. The company has a market capitalization of $21.76 million, a P/E ratio of -0.22 and a beta of -2.00. The company has a quick ratio of 10.15, a current ratio of 10.15 and a debt-to-equity ratio of 0.23. Metacrine, Inc. has a fifty-two week low of $0.39 and a fifty-two week high of $4.84.
Several large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in Metacrine by 1,236.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 210,435 shares of the company’s stock worth $142,000 after purchasing an additional 194,694 shares in the last quarter. Virtu Financial LLC acquired a new position in Metacrine during the 4th quarter worth approximately $82,000. Acadian Asset Management LLC acquired a new position in Metacrine during the 4th quarter worth approximately $56,000. Bank of America Corp DE grew its holdings in Metacrine by 234.3% during the 4th quarter. Bank of America Corp DE now owns 238,376 shares of the company’s stock worth $161,000 after acquiring an additional 167,072 shares during the last quarter. Finally, Cim Investment Management Inc. grew its holdings in Metacrine by 100.0% during the 4th quarter. Cim Investment Management Inc. now owns 38,108 shares of the company’s stock worth $78,000 after acquiring an additional 19,054 shares during the last quarter. Institutional investors own 40.99% of the company’s stock.
About Metacrine (Get Rating)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH.
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.